| Filed On | Filing |
|---|---|
| 22 Oct 2026 | 144 |
| 15 Oct 2026 | SCHEDULE 13G/A |
| 15 Oct 2026 | Proxy statement: special meeting on November 13, 2026 |
| 07 Oct 2026 | SCHEDULE 13G/A |
| 05 Oct 2026 | PRE 14A |
| 23 Sep 2026 | 144 |
| 22 Sep 2026 | 144 |
| 18 Sep 2026 | 144 |
| 18 Sep 2026 | SCHEDULE 13G |
| 16 Sep 2026 | SCHEDULE 13G |
| 15 Sep 2026 | SCHEDULE 13D |
| 11 Sep 2026 | SCHEDULE 13D |
| 11 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +9 more
Each subsidiary listed above is wholly owned, directly or indirectly, by Korsana Biosciences, Inc. |
| 10 Sep 2026 |
Form 4: Pernice Michelle Patricia, Director
Granted 48,445 Stock Option (Right to Buy) |
| 10 Sep 2026 |
Form 4: Shah Nimish P, Director
Granted 48,445 Stock Option (Right to Buy) |
| 10 Sep 2026 |
Form 4: Fairmount Funds Management Llc, Director and 4 others
Granted 48,445 Stock Option (Right to Buy) |
| 10 Sep 2026 |
Form 4: Gottesdiener Andrew, Director
Granted 48,445 Stock Option (Right to Buy) |
| 10 Sep 2026 |
Form 3: Violin Jonathan, Director
Holds 207,400 shares of Common Stock |
| 10 Sep 2026 | Form 3: Leoni Matthew James, Chief Medical Officer |
| 10 Sep 2026 | Form 3: Pernice Michelle Patricia, Director |
Loading...
